Allarity Therapeutics Doses First Patient in Dovitinib and Stenoparib Combination Phase 1b Clinical Trial

(24/7 MARKET NEWS) – Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced, this morning, that it dosed the first patient in a Phase 1b clinical study evaluating the combination of stenoparib and dovitinib for the treatment of advanced solid tumors, including ovarian cancer.

Allarity Therapeutics is trading at $0.15, up $0.045 (+40.95%), on 3.1 million premarket shares.

Its 52-week trading range is $0.105 to $3.38. This morning’s announcement is an opportunity for ALLR to bounce off of its 52-week lows and potentially run to the $0.20+ resistance levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist